Switch studies in virologically suppressed patients

Switch to LPV/r monotherapy
KalMo Study: Switch to LPV/r monotherapy
Original article : HIV Clin Trials. 2009 Nov-Dec;10(6):368-74 – EP Nunes
Last update : 28/03/2014

Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK

  • Switching to LPV/r monotherapy is effective, safe and well tolerated through 96 weeks

Design :

Endpoint :

  • Primary endpoint: proportion of patients with HIV-1 RNA < 80 c/mL at W96 (ITT, missing equals failure analysis)
  • Secondary endpoints: virologic failure (2 consecutive HIV-1 RNA > 500 c/mL), AIDS-defining illnesses, CD4, safety, adverse events

Baseline characteristics and patient disposition :

Virologic outcome :

Virologic outcome :

  • 1 virologic failure (confirmed HIV-1 RNA > 500 c/mL) in each group. No resistance mutation on genotype
  • No difference in CD4 changes between groups
  • GI adverse events more frequent in the monotherapy group: 24 vs 10 (p = 0.001)
  • 5 patients in the triple therapy group underwent regimen changes due to drug-related toxicities



Back to Table of Contents

Copyright AEI 2020 | Links | Contact | Editorial Office | Faculty and Disclosure | Terms of use aei